Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Carmustine-loaded Catanionic Solid Lipid Nanoparticles With Serotonergic 1B Receptor Subtype Antagonist For In Vitro Targeted Delivery To Inhibit Brain Cancer Growth

Y. Kuo, Cheng-chin Wang
Published 2015 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Solid lipid nanoparticles (SLNs) stabilized with catanionic surfactants and grafted with serotonergic 1B receptor subtype antagonist (S1BRSA) were employed to encapsulate carmustine (BCNU) (denoted as S1BRSA/BCNU–CASLNs) for brain-targeted delivery. BCNU–CASLNs were fabricated by microemulsion method and the monolayer of human brain-microvascular endothelial cells (HBMECs) regulated by human astrocytes were treated with S1BRSA/BCNU–CASLNs to evaluate the BCNU permeability across the blood–brain barrier. An increase in the catanionic surfactant concentration promoted the surface charge and toxicity to HBMECs and U87MG cells of glioblastoma multiforme (GBM). The catanionic surfactant concentration at 1 mM yielded the smallest particle size and highest entrapment efficiency of BCNU. An increase in the weight percentage of Compritol 888 ATO (CA) reduced the particle size and surface charge and enhanced the grafting efficiency of S1BRSA, viability of HBMECs, and BCNU permeability. A maximal entrapment efficiency of BCNU emerged at 50% (w/w) CA. An increase in the S1BRSA concentration reduced the grafting efficiency of S1BRSA and improved the BCNU permeability. The developed S1BRSA/BCNU–CASLNs, showing an anticancer efficacy against the growth of malignant GBM U87MG cells, were efficacious carriers in delivering BCNU to HBMECs and could be administered by intravenous injection in clinical application.
This paper references
10.1016/j.ijpharm.2014.02.008
Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline.
Y. Kuo (2014)
10.1016/j.biomaterials.2013.08.083
Polybutylcyanoacrylate nanoparticles for delivering hormone response element-conjugated neurotrophin-3 to the brain of intracerebral hemorrhagic rats.
Chiu-Yen Chung (2013)
10.1016/j.colsurfb.2010.11.037
Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
Y. Kuo (2011)
10.1016/j.colsurfb.2010.02.013
Biological activity of SDS-CTAB cat-anionic vesicles in cultured cells and assessment of their cytotoxicity ending in apoptosis.
Cecilia Aiello (2010)
10.1158/1078-0432.CCR-06-2935
Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors
M. Morris (2007)
10.1016/j.colsurfb.2011.04.005
Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier.
Y. Kuo (2011)
10.1002/jcb.24033
Characterization of hydrophobic anti‐cancer drug‐loaded amphiphilic peptides as a gene carrier
J. H. Park (2012)
10.1016/j.colsurfb.2011.10.035
Expression of P-glycoprotein and multidrug resistance-associated protein on human brain-microvascular endothelial cells with electromagnetic stimulation.
Y. Kuo (2012)
10.1177/0748730405283765
Photic Entrainment Is Altered in the 5-HT 1B Receptor Knockout Mouse
P. J. Sollars (2006)
10.1016/j.ijpharm.2012.11.042
Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles.
R. Bhandari (2013)
10.1016/S0378-5173(01)00882-1
Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages.
N. Schöler (2002)
10.1016/j.colsurfb.2009.04.004
Impact of arginine-modified solid lipid nanoparticles on the membrane charge of human brain-microvascular endothelial cells.
Y. Kuo (2009)
10.1172/JCI119125
Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels.
P. Golden (1997)
10.1016/J.JNEUROIM.2004.05.004
CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer
M. Callahan (2004)
10.1002/jcp.20327
Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi‐chaperone complex in human epidermoid cancer cells
M. Caraglia (2005)
10.1016/J.VETIMM.2005.08.025
Growth and characterisation of a cell culture model of the feline blood-brain barrier.
N. Fletcher (2006)
10.1021/JP303803M
Surface Molecular Composition and Electrical Property of Cationic Solid Lipid Nanoparticles with Assembled Lipid Layer Mediated by Noncovalent Interactions
Y. Kuo (2012)
10.1016/j.biomaterials.2010.09.065
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
M. Hua (2011)
10.1002/JPS.2600550509
The Antitumor Agent, 1,3-bis(2-chloroethyl)-1-nitrosourea
T. Loo (1966)
10.1016/0378-5173(96)04539-5
Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles
R. Mueller (1996)
10.1016/j.colsurfb.2008.02.006
Flow cytometric characterization of interactions between U-937 human macrophages and positively charged catanionic vesicles.
J. Kuo (2008)
10.1016/J.IJPHARM.2005.07.031
How porosity and size affect the drug release mechanisms from PLGA-based microparticles.
D. Klose (2006)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1016/J.JTICE.2013.09.024
Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain
Y. Kuo (2014)
10.1016/J.JTICE.2012.06.008
Development of ethosome-like catanionic vesicles for dermal drug delivery
Y. Liu (2012)
10.1016/S0378-5173(00)00562-7
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
A. Miglietta (2000)
10.1155/2013/509628
Fluorescent Silica Nanoparticles in the Detection and Control of the Growth of Pathogen
K. Chitra (2013)
10.7150/thno.8074
Combining Microbubbles and Ultrasound for Drug Delivery to Brain Tumors: Current Progress and Overview
H. Liu (2014)
10.1021/LA011647F
Adsorbed Layer Structure of Cationic and Anionic Surfactants on Mineral Oxide Surfaces
J. Schulz (2002)
10.1002/1097-4547(20000701)61:1<82::AID-JNR10>3.0.CO;2-E
Antidepressant‐induced regulation of 5‐HT1b mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation
J. Anthony (2000)
10.1016/j.biomaterials.2011.05.047
Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas.
Hung-Wei Yang (2011)
10.1016/S0142-9612(02)00578-1
The production and characteristics of solid lipid nanoparticles (SLNs).
DongZhi Hou (2003)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/0006-8993(94)91889-9
Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studies using fast cyclic voltammetry in vitro
J. O'Connor (1994)
10.2147/IJN.S12125
Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method
Z. Urbán-Morlán (2010)
10.1517/17425240802567846
Polymeric carriers: role of geometry in drug delivery
Eric A Simone (2008)
10.1016/J.JCIS.2007.03.035
The aqueous catanionic system sodium perfluorooctanoate-dodecyltrimethylammonium bromide at low concentration.
J. L. López-Fontán (2007)
10.1016/j.biomaterials.2014.03.082
Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin.
Y. Kuo (2014)
10.1371/journal.pone.0029424
Organically Modified Silica Nanoparticles Are Biocompatible and Can Be Targeted to Neurons In Vivo
Farda Barandeh (2012)
10.1016/j.neuint.2004.08.007
Selective 5-HT1B receptor agonist reduces serotonin synthesis following acute, and not chronic, drug administration: results of an autoradiographic study
Shu Hasegawa (2005)
10.1016/j.colsurfb.2012.06.002
Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia.
Y. Kuo (2013)
10.1021/jp711420g
Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide.
Y. Kuo (2008)
10.3892/or.2011.1459
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
L. Han (2012)
10.1038/252252A0
Liposomes as immunological adjuvants
A. Allison (1974)
10.1046/j.1471-4159.1997.68031159.x
Potentiation of the Fluoxetine‐Induced Increase in Dialysate Levels of Serotonin (5‐HT) in the Frontal Cortex of Freely Moving Rats by Combined Blockade of 5‐HT1A and 5‐HT1B Receptors with WAY 100,635 and GR 127,935
A. Gobert (1997)
10.1002/btpr.1834
Cationic solid lipid nanoparticles with cholesterol‐mediated surface layer for transporting saquinavir to the brain
Y. Kuo (2014)
10.1016/j.critrevonc.2008.05.005
Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies.
A. A. Argyriou (2009)
10.3109/1061186X.2013.812094
Solid lipid nanoparticles carrying chemotherapeutic drug across the blood–brain barrier through insulin receptor-mediated pathway
Y. Kuo (2013)
10.1016/S0306-4522(98)00196-1
Endothelial expression of the 5-hydroxytryptamine1B antimigraine drug receptor in rat and human brain microvessels
M. Riad (1998)
10.1016/J.COLSURFA.2009.11.039
Physicochemistry of the binary interacting mixtures of cetylpyridinium chloride (CPC) and sodium dodecylsulfate (SDS) with special reference to the catanionic ion-pair (coacervate) behavior
Kajari Maiti (2010)
10.3171/JNS.1988.68.1.0001
Chemotherapy for malignant gliomas.
P. Kornblith (1988)
10.1016/J.CHEMPHYSLIP.2007.06.213
The influence of fatty acids on model cholesterol/phospholipid membranes.
K. Hąc-Wydro (2007)
10.1016/j.biomaterials.2011.01.048
Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor.
Y. Kuo (2011)
10.1016/j.colsurfb.2011.05.014
Regulation of endocytosis into human brain-microvascular endothelial cells by inhibition of efflux proteins.
Y. Kuo (2011)
10.1124/JPET.105.083501
Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities
R. Hansen (2005)
10.1016/J.IJPHARM.2005.03.034
Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer.
Gang Soo Chae (2005)
10.1093/AJCN/50.6.1370
Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity.
O. Lutz (1989)
10.1016/J.CTRV.2006.01.003
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
M. Halatsch (2006)
10.1007/S11746-998-0245-Y
Phase transitions and polymorphism of cocoa butter
C. Loisel (1998)
10.1016/J.IJPHARM.2007.09.020
Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers.
Y. Kuo (2008)
10.1021/JP072876Z
Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells.
Y. Kuo (2007)
10.3390/ijms131013275
The Effect of Sodium Dodecyl Sulfate (SDS) and Cetyltrimethylammonium Bromide (CTAB) on the Properties of ZnO Synthesized by Hydrothermal Method
Donya Ramimoghadam (2012)
10.1208/s12249-009-9199-0
Preparation and Evaluation of Miconazole Nitrate-Loaded Solid Lipid Nanoparticles for Topical Delivery
M. Bhalekar (2009)
10.1016/J.IJPHARM.2007.03.012
Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Y. Kuo (2007)
Nitrosourea pharmacodynamics in relation to the central nervous system.
M. Walker (1976)
Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas
D. Bota (2007)
10.1016/J.JCONREL.2006.05.031
BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.
X. Xu (2006)
10.1016/j.colsurfb.2011.02.011
Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells.
Y. Kuo (2011)
10.1016/j.biomaterials.2013.03.013
Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles.
Y. Kuo (2013)
10.1016/j.toxlet.2009.12.011
Gender and species differences in triadimefon metabolism by rodent hepatic microsomes.
S. Crowell (2010)
10.1093/BJA/89.5.762
Effect of diclofenac on cerebral blood flow velocity in patients with supratentorial tumours.
S. Jones (2002)
10.1016/S0091-3057(00)00232-X
Effect of 5-HT1B Receptor Ligands on Self-administration of Ethanol in an Operant Procedure in Rats
D. Tomkins (2000)
10.1016/J.JTICE.2014.01.017
Solid lipid nanoparticles with surface antibody for targeting the brain and inhibiting lymphatic phagocytosis
Y. Kuo (2014)
10.1007/s11947-012-0845-2
Hesperetin-Loaded Solid Lipid Nanoparticles and Nanostructure Lipid Carriers for Food Fortification: Preparation, Characterization, and Modeling
Milad Fathi (2012)
10.1016/J.PHARMTHERA.2005.12.004
5-hydroxytryptamine receptors in the human cardiovascular system.
A. Kaumann (2006)
10.1021/jp803105n
Molecular interactions of cationic and anionic surfactants in mixed monolayers and aggregates.
B. Sohrabi (2008)
Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs.
J. V. van Bree (1988)
10.1016/J.IJPHARM.2007.03.022
Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Veerawat Teeranachaideekul (2007)
10.1016/J.MATCHEMPHYS.2004.04.022
Electrochemical deposition of nickel/SiC composites in the presence of surfactants
M. Ger (2004)
10.1159/000227399
High-sensitivity antitumor drug sensitivity testing.
T. Kondo (1994)
10.1002/jbm.a.34442
Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency.
M. Callewaert (2013)
10.1016/S0378-5173(98)00092-1
Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions
C. Freitas (1998)
10.1016/S0142-9612(01)00030-8
Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake.
G. Fontana (2001)
10.1016/J.CBI.2003.08.001
In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan.
L. Yu (2003)
10.2147/IJN.S30085
Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil
F. Shi (2012)
10.2217/nnm.11.25
Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles.
Y. Kuo (2011)
10.1016/j.addr.2009.03.005
In vitro assessments of nanomaterial toxicity.
Clinton F Jones (2009)
10.1021/LA0361417
Optical spectroscopic and TEM studies of catanionic micelles of CTAB/SDS and their interaction with a NSAID.
Hirak Chakraborty (2004)
10.1016/S0928-0987(00)00152-4
Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug.
P. Gaillard (2000)
10.1016/S0091-3057(01)00712-2
Anxiogenic-like effect of serotonin1B receptor stimulation in the rat elevated plus-maze
D. Lin (2002)
10.1016/j.biomaterials.2013.07.097
Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
L. Qian (2013)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/S0306-4522(99)00322-X
5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety
B. Grimaldi (1999)
Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells.
M. Smith (1989)
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
L. Rhines (2000)



This paper is referenced by
10.21203/rs.3.rs-116419/v1
Mixed Alkyltrimethylammonium-Alkylcarboxylate Surfactants Systems: A Potential Anti-Proliferation Agent for MDA-MB-231 Cancer Cell Line
H. Lim (2020)
10.3109/1061186X.2015.1132223
Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles
Y. Kuo (2016)
10.1016/J.JTICE.2018.03.028
Current development of nanocarrier delivery systems for Parkinson's disease pharmacotherapy
Y. Kuo (2018)
10.1016/j.drudis.2019.10.005
Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.
Fakhara Sabir (2019)
10.1016/J.JTICE.2015.12.012
Delivery of doxorubicin to glioblastoma multiforme in vitro using solid lipid nanoparticles with surface aprotinin and melanotransferrin antibody for enhanced chemotherapy
Y. Kuo (2016)
10.1002/jps.24388
Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with p-aminophenyl-α-D-manno-pyranoside and folic acid.
Y. Kuo (2015)
10.1016/j.ijpharm.2017.07.049
Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
A. Miranda (2017)
10.1007/978-3-030-06115-9_15
Brain-Targeted Drug Delivery with Surface-Modified Nanoparticles
Sunita Lahkar (2019)
10.1016/j.jconrel.2017.08.033
Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases
C. Tapeinos (2017)
10.1016/j.msec.2016.05.119
Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies.
M. Geszke-Moritz (2016)
10.2174/1381612825666190903155321
Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery.
Kuldeep Rajpoot (2019)
10.1016/j.ijpharm.2015.12.054
Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation.
Y. Kuo (2016)
10.1002/btpr.2214
Conjugation of melanotransferrin antibody on solid lipid nanoparticles for mediating brain cancer malignancy
Y. Kuo (2016)
10.1016/J.COLSURFA.2016.06.034
Preparation and investigation of solid lipid nanoparticles for drug delivery
Gokce Dicle Kalaycioglu (2016)
Semantic Scholar Logo Some data provided by SemanticScholar